Fingerpaint Group's Bill McEllen to Receive Prestigious Industry Person of the Year Award
McEllen's visionary leadership and people-first empowering mindset praised as a driving force behind the agency's success.
CEDAR KNOLLS, N.J., April 21, 2025 /PRNewswire/ -- Fingerpaint Group Global President Bill McEllen was named Industry Person of the Year by Med Ad News and will be honored at the 36th annual Manny Awards in New York City.
The award, presented to an industry leader based on their contribution and dedication to the healthcare communications industry, business vision, and participation in charitable ventures, is selected by the editors of Med Ad News.
"Being named Industry Person of the Year is not just an honor—it's a reminder of the relentless pursuit of excellence that drives us every day," said McEllen. "This recognition isn't about me; it's about the vision, the courage, and the passion that every person who is a part of Fingerpaint Group brings to life. We're here to challenge the status quo, to think differently, and to create something that matters."
McEllen joined Fingerpaint Group in 2016, serving as partner and head of the Saratoga Springs, New York, office before rising through the ranks to Global President in 2021. Prior to that, McEllen successfully led a number of renowned McCann agencies. The first decade of his career was spent on the client side in sales and marketing roles for global pharmaceutical companies. McEllen has always believed in leveraging his insight from this valuable time to make every partner experience count.
As Global President of Fingerpaint Group, he chairs the executive leadership team and is responsible for the strategic direction of the organization. In just under 10 years, the agency has grown by more than 10 times, acquired numerous companies, garnered 5 Agency of the Year awards, and been honored as a Best Place to Work.
According to Med Ad News' announcement, he leads with a visionary focus and a people-first empowering mindset and has helped transform Fingerpaint Group into a modern healthcare network. Fingerpaint Group's meteoric rise to a top 20 US healthcare marketing network is 100% attributed to McEllen's unique leadership style, which is rooted in the belief of putting his people's interests ahead of his own.
"Bill empowers those around him, fostering an environment where people can thrive," said Ed Mitzen, Founder of Fingerpaint Group. "Humble and generous, Bill doesn't seek the spotlight for himself but instead creates opportunities for his team at Fingerpaint Group to shine—both with clients and within the industry."
McEllen will accept the honor during the 36th annual Manny Awards on April 24 in New York City.
About Fingerpaint Group
Fingerpaint Group, a top 20 healthcare marketing agency, is a vibrant palette of people and expertise spanning the complete spectrum of life science solutions. Where others see limits, we see opportunity for originality. We craft with courage and purpose, pairing imagination with innovation and blending skills that transcend barriers and silos. We achieve success by painting with richer hues of genuine partnership, unlocking the greatness of brands and transforming them into enduring masterpieces. Visit us at www.fingerpaint.com
Contact:
Michelle Maskaly
Michelle.maskaly@fingerpaint.com
732-713-6716
View original content to download multimedia:https://www.prnewswire.com/news-releases/fingerpaint-groups-bill-mcellen-to-receive-prestigious-industry-person-of-the-year-award-302432659.html
SOURCE Fingerpaint Group
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Energenesis Biomedical to Unveil Promising Parkinson's Disease Therapy, ENERGI-F705PD, at BIO International 2025
TAIPEI, June 11, 2025 /PRNewswire/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company pioneering cellular energy restoration therapeutics, today announced its participation in the BIO International Convention 2025, taking place June 16–19 in Boston, MA. The company will be located at Booth #1645 within the Taiwan Pavilion, to showcase its innovative ENERGI Platform and provide a key update on its investigational Parkinson's disease (PD) therapy, ENERGI-F705PD, a first-in-class treatment with disease-modifying potential. Key Highlights: ENERGI-F705PD is a first-in-class, oral sustained-release therapy in development for Parkinson's disease, designed to address the underlying pathogenesis. Topline data from the Phase I trial in healthy subjects are anticipated in September 2025, following successful completion of recruitment. ENERGI-F705PD aims to combat the root causes of Parkinson's by reducing alpha-synuclein aggregation, enhancing antioxidant capacity, and boosting dopamine synthesis. "We are eager to present the exciting progress of our ENERGI-F705PD program at BIO International 2025," said Dr. Han-Min Chen, CEO of Energenesis Biomedical. "Parkinson's disease remains a challenging condition with significant unmet needs. Our approach focuses on restoring cellular energy and combating critical pathogenesis of PD, offering a potential disease-modifying solution for patients. We look forward to sharing our latest data and exploring potential partnerships that can accelerate the development of this important therapy." About ENERGI-F705PD ENERGI-F705PD is a novel small-molecule drug delivered in an oral sustained-release formulation. It is designed to enhance cellular ATP and antioxidant production by engaging the purine salvage, glycolysis, and pentose phosphate pathways. This multi-pronged mechanism of action directly addresses key pathological hallmarks of Parkinson's disease: Reduce and Prevent α-Synuclein Aggregation: Elevated ATP acts as a hydrotrope, helping prevent the intracellular aggregation of misfolded α-synuclein, a central pathogenic hallmark of PD. Increase Reducing Power (antioxidant): ENERGI-F705PD upregulates the pentose phosphate pathway (PPP), leading to increased NADPH production and enhanced cellular antioxidant defense. Increase Tyrosine Hydroxylase Expression/activity: By optimizing cellular energy metabolism and engaging the purine salvage pathway, ENERGI-F705PD also enhances the expression and activity of tyrosine hydroxylase (TH), the key enzyme in dopamine synthesis, thereby helping restore neurotransmitter levels in the brains of PD patients. About Energenesis Biomedical Energenesis Biomedical Co., Ltd. (TWSE: 6657) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics that restore cellular energy and activate intrinsic repair mechanisms. By combining proprietary small-molecule innovation with AI-driven drug repurposing, Energenesis Biomedical aims to accelerate the development of treatments for unmet medical needs across various therapeutic areas, including neurodegenerative diseases, chronic wounds, and rare disorders. The company's robust pipeline includes: ENERGI-F705PD: Oral tablet for Parkinson's disease (Phase I) ENERGI-F703DFU: Gel for Diabetic foot ulcers (Phase III) ENERGI-F701: Tonic for Alopecia (Phase II completed) ENERGI-F703EB: Cream for Epidermolysis bullosa (EB), granted FDA Orphan Drug and Rare Pediatric Disease designation, and EMA orphan designation(Preparing for Phase II) For more information, please visit Contact: Business Development Team Email: partnership@ View original content: SOURCE ENERGENESIS BIOMEDICAL CO., LTD. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
3 hours ago
- Business Insider
Bill downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Chris Quintero downgraded Bill (BILL) to Equal Weight from Overweight with a price target of $55, down from $60. Many of the firm's prior bullish thesis assumptions, including small business spending improvement and take rate expansion, are not playing out, the analyst tells investors in a research note. The firm further cites an increasingly uncertain macro environment and believes that FY26 estimates are looking too high given the lack of positive catalysts. Confident Investing Starts Here:
Yahoo
4 hours ago
- Yahoo
Marelli Initiates Voluntary U.S. Chapter 11 Proceedings to Strengthen Financial Position and Facilitate a Value-Maximizing Restructuring
Reaches Restructuring Support Agreement ("RSA") with Approximately 80% of Lenders Secures Commitment of $1.1 Billion in Debtor-in-Possession ("DIP") Financing from Lenders 100% of Secured Debt to be Eliminated Access to New Liquidity Designed to Support Normal Course Business Operations; Marelli will Continue Delivering Reliable, High-Performance Products for Customers TOKYO, June 11, 2025 /PRNewswire/ -- Marelli Holdings Co. Ltd. ("Marelli" or the "Company"), a global technology partner to the automotive industry, today announced that it has commenced voluntary chapter 11 cases in the United States Bankruptcy Court for the District of Delaware in order to comprehensively restructure its long‑term debt obligations. Approximately 80% of the Company's lenders have signed an agreement to support the restructuring (the "Restructuring Support Agreement"), which will deleverage Marelli's balance sheet and strengthen its liquidity position. Throughout this process and moving forward, Marelli does not expect any operational impact from the chapter 11 process, and the Company will continue to work closely with its customers, suppliers, and partners to innovate and invest in its portfolio of advanced technologies that will differentiate the vehicles of the future and transform mobility. A complete list of the Marelli affiliates involved in the chapter 11 cases can be found at "At Marelli, we have been proactive in making necessary adjustments to stabilize our financial position so that we can continue to deliver long-term benefits for our valued customers, partners and employees," said David Slump, President and CEO, Marelli. "While we are pleased with our recent progress and profitability, industry-wide market pressures have created a gap in working capital that must be addressed. After careful review of the Company's strategic alternatives, we have determined that entering the chapter 11 process is the best path to strengthen Marelli's balance sheet by converting debt to equity, while ensuring we continue operating as usual. Taking this action now provides access to new liquidity to fund our long-term growth and innovation pipeline, and ensures our customers and partners all over the world can continue to rely on Marelli for on-time delivery of advanced technologies that shape the vehicles of the future." Mr. Slump continued, "Marelli's focus on innovation, digitalization and technology has never been stronger. As we move through this process, we will continue to serve our customers and work with our suppliers and partners as they have come to expect. We are also grateful for the hard work and dedication of our employees who remain focused on delivering the best service possible." To support the Company during this process, Marelli has received a significant commitment for $1.1 billion in debtor-in-possession financing ("DIP Financing") from its lenders. This additional capital underscores lenders' continued support and confidence in the Company's underlying business and its long-term potential. Upon Court approval, the DIP Financing, coupled with cash generated from the Company's ongoing operations, is expected to provide sufficient liquidity to support the Company through the chapter 11 process. In addition to the DIP Financing, the Restructuring Support Agreement provides for a comprehensive deleveraging transaction through which the DIP Lenders will take ownership of the business upon emergence from chapter 11, subject to a 45-day overbid process. Marelli filed a number of customary first day motions seeking Court approval to continue its operations throughout the chapter 11 process, including, among other things, payment of employee wages and benefits without interruption and continuation of programs that are integral to customer relationships. The Company anticipates receiving Court approval for these requests and intends to continue honoring its obligations to key stakeholders post‑filing, including by satisfying payment obligations to suppliers for goods and services provided in accordance with customary terms after the filing. The Company will be working with its suppliers regarding obligations which arose before the chapter 11 filing to reach agreements on payment terms. Additional InformationAdditional information about Marelli's financial restructuring is available at Court filings and other information related to the proceedings, including the claims process, are available on a separate website administrated by the Company's claims agent, Verita, at by calling Verita's representatives toll-free at 877-606-7509 or +1 310-751-2626 for calls originating outside of the U.S. or Canada; or by emailing Verita at AdvisorsKirkland & Ellis LLP is serving as legal counsel to Marelli. PJT Partners Inc. is serving as financial advisor and Alvarez & Marsal LLC is serving as restructuring advisor to Marelli. Akin Gump Strauss Hauer & Feld LLP, Houlihan Lokey, and AlixPartners LLP are serving as advisors to an ad hoc group of lenders. About MarelliMarelli is a global mobility technology supplier to the automotive sector. With a strong and established track record in innovation and manufacturing excellence, our mission is to transform the future of mobility through working with customers and partners to create a safer, greener, and better-connected world. With around 45,000 employees worldwide, the Marelli footprint includes over 150 sites globally. View original content: SOURCE Marelli
